Literature DB >> 10897255

p53: biology and role for cellular radiosensitivity.

J Dahm-Daphi1.   

Abstract

PURPOSE: p53 is the most commonly mutated gene in human tumors with large impact on cellular biology and response to radiation. Many excellent reviews are available on various aspects but for several years none about the role of p53 for radiosensitivity. The latter is the aim of the present paper.
METHODS: Review of the literature.
RESULTS: p53 is a regulator of apoptosis mainly in hematopoetic tissue. In normal tissue and solid tumors presumably other functions have more impact on the cellular response. p53 controls cell-cycle progression after irradiation and also DNA-repair, namely homologous and non-homologous recombination. Mutations of p53 alter these functions which may be responsible for an enhanced cellular and tumor radioresistance. At present only few reports were able to show that under tightly controlled conditions loss of p53 wild-type function leads to enhanced radioresistance. A general proof is still lacking.
CONCLUSIONS: The emerging picture in the year 2000 shows p53 as a central protein in a multi-enzyme multi-function network which is far from being fully understood. Although p53 appears to be a major regulator it is certainly not the unreplaceable component the loss of which uniformly determines radioresistance. Only further understanding of modifiers and co-operators in the cell and in the specific tissue context will elucidate p53's role for radiosensitivity and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897255     DOI: 10.1007/s000660050010

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  8 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Authors:  Peter L Roberson; Lauren B Smith; Meredith A Morgan; Matthew J Schipper; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2017-10-30       Impact factor: 3.099

3.  Simultaneous analysis of p53 protein expression and cell proliferation in irradiated human lymphocytes by flow cytometry.

Authors:  Rafael de Freitas E Silva; Neyliane Frassinetti Gonçalves Dos Santos; Valéria Rěgo Alves Pereira; Ademir Amaral
Journal:  Dose Response       Date:  2013-08-27       Impact factor: 2.658

4.  Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer.

Authors:  B Pajares; L Perez-Villa; J M Trigo; M D Toledo; M Alvarez; B Jimenez; J A Medina; V de Luque; J M Jerez; E Alba
Journal:  Clin Transl Oncol       Date:  2013-11-06       Impact factor: 3.405

5.  ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells.

Authors:  Bianca M Sirbu; Sarah J Lachmayer; Verena Wülfing; Lara M Marten; Katie E Clarkson; Linda W Lee; Liliana Gheorghiu; Lee Zou; Simon N Powell; Jochen Dahm-Daphi; Henning Willers
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

6.  WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.

Authors:  Nataliya Zhukova; Vijay Ramaswamy; Marc Remke; Dianna C Martin; Pedro Castelo-Branco; Cindy H Zhang; Michael Fraser; Ken Tse; Raymond Poon; David J H Shih; Berivan Baskin; Peter N Ray; Eric Bouffet; Peter Dirks; Andre O von Bueren; Elke Pfaff; Andrey Korshunov; David T W Jones; Paul A Northcott; Marcel Kool; Trevor J Pugh; Scott L Pomeroy; Yoon-Jae Cho; Torsten Pietsch; Marco Gessi; Stefan Rutkowski; Laszlo Bognár; Byung-Kyu Cho; Charles G Eberhart; Cecile Faure Conter; Maryam Fouladi; Pim J French; Wieslawa A Grajkowska; Nalin Gupta; Peter Hauser; Nada Jabado; Alexandre Vasiljevic; Shin Jung; Seung-Ki Kim; Almos Klekner; Toshihiro Kumabe; Boleslaw Lach; Jeffrey R Leonard; Linda M Liau; Luca Massimi; Ian F Pollack; Young Shin Ra; Joshua B Rubin; Erwin G Van Meir; Kyu-Chang Wang; William A Weiss; Karel Zitterbart; Robert G Bristow; Benjamin Alman; Cynthia E Hawkins; David Malkin; Steven C Clifford; Stefan M Pfister; Michael D Taylor; Uri Tabori
Journal:  Acta Neuropathol Commun       Date:  2014-12-24       Impact factor: 7.801

7.  Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.

Authors:  Bella Pajares; Jose M Trigo; Maria D Toledo; Martina Álvarez; Carlos González-Hermoso; Antonio Rueda; Jose A Medina; Vanessa de Luque; Jose M Jerez; Emilio Alba
Journal:  BMC Cancer       Date:  2013-01-18       Impact factor: 4.430

Review 8.  Repair of radiation damage to DNA.

Authors:  H Willers; J Dahm-Daphi; S N Powell
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.